WORLD NEWS
-
Moderna’s Spikevax gains full FDA approval for vulnerable children
Previously, Moderna’s COVID-19 vaccine (mRNA-1273) was only available for this younger age group under an Emergency Use Authorization (EUA).
-
-
China’s Everest Medicines pioneers AI-driven mRNA therapies at 2025 R&D day
The event highlighted the company’s progress in developing a fully integrated and localized AI+mRNA platform that accelerates the creation of innovative therapies, particularly in cancer and autoimmune diseases.
-
AbbVie pays US$700M upfront for Ichnos Glenmark’s promising multiple myeloma drug
Under the deal, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across major markets including North America, Europe, Japan, and Greater China.
-
Merck bets big on COPD treatment Ohtuvayre with US$10B Verona Pharma acquisition
Merck aims to enhance its respiratory portfolio with the acquisition of Ohtuvayre (ensifentrine), a newly approved inhaled treatment for chronic obstructive pulmonary disease (COPD), also known as “smoker’s lung.”
-
Charité partners with Siemens Healthineers to revolutionize preventive healthcare in Germany
Charité and Siemens Healthineers will launch joint research projects to create faster and more precise diagnostic and treatment methods using AI.
-
Eli Lilly’s once-weekly insulin Efsitora Alfa shows strong Phase 3 results for Type 2 diabetes
Across all three trials, efsitora demonstrated non-inferior reductions in A1C levels compared to standard daily basal insulins.
-
Russia advances AI in healthcare with a new educational Center for Diagnostics and Telemedicine in partnership with RTU MIREA
The partnership resulted in a unique educational program that incorporates insights from the Moscow Experiment, a groundbreaking project in AI for medical imaging.
-
Chugai Pharmaceutical partners with Gero to develop AI-Powered antibody therapies for age-related diseases
The agreement grants Chugai exclusive worldwide rights to research, develop, manufacture, and sell antibodies derived from the identified targets.
-
Italy appoints special commissioner to fast-track Novo Nordisk’s US$2.34B expansion
This decision is aimed at ensuring the swift and efficient delivery of Novo Nordisk’s promised investment of over 2 billion euros (US$2.34 billion) in a manufacturing facility located south of Rome.